Here’s Why I Think CompuGroup Medical Societas Europaea (FRA:COP) Might Deserve Your Attention Today

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it completely lacks a track record of revenue and profit. But as Warren Buffett has mused, ‘If you’ve been playing poker for half an hour and you still don’t know who the patsy is, you’re the patsy.’ When they buy such story stocks, investors are all too often the patsy.

If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in CompuGroup Medical Societas Europaea (FRA:COP). While that doesn’t make the shares worth buying at any price, you can’t deny that successful capitalism requires profit, eventually. While a well funded company may sustain losses for years, unless its owners have an endless appetite for subsidizing the customer, it will need to generate a profit eventually, or else breathe its last breath.

View our latest analysis for CompuGroup Medical Societas Europaea

How Fast Is CompuGroup Medical Societas Europaea Growing?

If a company can keep growing earnings per share (EPS) long enough, its share price will eventually follow. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Impressively, CompuGroup Medical Societas Europaea has grown EPS by 34% per year, compound, in the last three years. As a general rule, we’d say that if a company can keep up that sort of growth, shareholders will be smiling.

Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. The good news is that CompuGroup Medical Societas Europaea is growing revenues, and EBIT margins improved by 4.4 percentage points to 19%, over the last year. Ticking those two boxes is a good sign of growth, in my book.

You can take a look at the company’s revenue and earnings growth trend, in the chart below. For finer detail, click on the image.

DB:COP Income Statement, April 22nd 2019
DB:COP Income Statement, April 22nd 2019

Fortunately, we’ve got access to analyst forecasts of CompuGroup Medical Societas Europaea’s future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.

Are CompuGroup Medical Societas Europaea Insiders Aligned With All Shareholders?

Many consider high insider ownership to be a strong sign of alignment between the leaders of a company and the ordinary shareholders. So as you can imagine, the fact that CompuGroup Medical Societas Europaea insiders own a significant number of shares certainly appeals to me. In fact, hey own 55% of the company, so they will share in the same delights and challenged experienced by the ordinary shareholders. To me this is a good sign because it suggests they will be incentivised to build value for shareholders over the long term. And that holding is extremely valuable at the current share price, totalling €1.5b. Now that’s what I call some serious skin in the game!

Does CompuGroup Medical Societas Europaea Deserve A Spot On Your Watchlist?

You can’t deny that CompuGroup Medical Societas Europaea has grown its earnings per share at a very impressive rate. That’s attractive. I think that EPS growth is something to boast of, and it doesn’t surprise me that insiders are holding on to a considerable chunk of shares. So this is very likely the kind of business that I like to spend time researching, with a view to discerning its true value. Of course, just because CompuGroup Medical Societas Europaea is growing does not mean it is undervalued. If you’re wondering about the valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

You can invest in any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.